Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow (NASDAQ:ALLO) 2026-04-14
Allogene TherapeuticsAllogene Therapeutics(US:ALLO) Seeking Alpha·2026-04-14 15:02

技术访问问题 - 用户需在浏览器中启用Javascript和cookies以正常访问未来内容 [1] - 启用广告拦截器可能导致访问受阻 用户需禁用广告拦截器并刷新页面 [1]

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow (NASDAQ:ALLO) 2026-04-14 - Reportify